homepage-top-section

DZD4205 (Golidocitinib) is a selective JAK1 inhibitor in relapsed/refractory peripheral T-Cell lymphoma. The orally available, JAK1-specific inhibitor has showed that 21 (42.9%) out of the 49 patients have

Led by Perceptive Advisors, the financing round has seen participation from existing investors RA Capital Management, Wellington Management, and Moore Strategic Ventures. The new investors include Declaration Partners,

SBT101 is in development for compensating the disease-causing ABCD1 mutation. It is designed for reducing very long chain fatty acid (VLCFA) levels and increase ABCD1 expression for AMN

These patients have received at least one prior systemic therapy earlier. Adagrasib is an investigational, potent oral small-molecule therapy which is designed to shrink difficult-to-treat cancers that are

As per the terms of the collaboration, Adcentrx will specify the targets against which AvantGen will screen for new antibodies by making use of its yeast display system.

Lead founding investors Polaris Partners and Timothy A. Springer participated in the funding round, in addition to new investors Samsara BioCapital, Boxer Capital, GV, and management and founders.

As per the agreement, Healx intends to investigate the compound as part of a potential combination therapy for Fragile X syndrome and treatment for other indications. Fragile X

As part of the collaboration, both the companies will co-develop AVT23, an investigational compound, that is now in late development stage. The companies will develop the proposed biosimilar

Cabenuva has now been cleared for every-two-month dosing for the treatment of HIV-1 in people who are virologically suppressed on a stable regimen, with no prior treatment failure,